Drug maker Lupin today launched Drospirenone, Ethinyl Estradiol, Levomefolate Calcium tablets and Levomefolate Calcium tablets, used to prevent pregnancy, in the US market.
The company has launched the product in the US after having received approval from the US Food and Drug Administration (USFDA) earlier, Lupin said in a BSE filing.
Approval was granted in the strengths of 3 mg/ 0.02mg/ 0.451 mg and 0.451 mg.
Lupin's product is a generic equivalent of Bayer's Beyazs tablets.
Quoting IQVIA MAT June 2018 data, Lupin said Drospirenone, Ethinyl Estradiol and Levomefolate Calcium Tablets and Levomefolate Calcium Tablets had annual sales of approximately USD 80.8 million in the US.
Lupin shares were trading 0.38 per cent up at Rs 910.60 apiece on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app